Objective: Lennox-Gastaut syndrome (LGS) is a severe and treatment-resistant epilepsy syndrome characterized by multiple subtypes of intractable seizures, moderate to severe cognitive impairment, and slow spike-wave complexes on electroencephalographic (EEG) recordings. Lennox-Gastaut syndrome is also associated with increased risk for injury, reduced quality of life, long-term disability, and early mortality. By evaluating private and public US medical insurance claims, we quantified healthcare utilization and direct costs in patients with possible LGS. Methods: Commercial and Medicaid insurance claims (Truven Health Analytics) from October 2010 to September 2015 were queried to identify patients with intractable epilepsy, intellectual disability, ≥ 1 prescription for selected antiepileptic drugs (AEDs), and ≥2 years of continuous enrollment. To identify patients with LGS in the absence of a specific International Classification of Diseases ICD-9 diagnosis code, current or prior rufinamide use was selected as a disease indicator of LGS per previously published methodology. Characteristics significantly predictive of rufinamide use were identified with multivariate regression by comparing groups with and without LGS, then assessed in non-rufinamide users fulfilling all other inclusion criteria. Controls without epilepsy, seizures, or prescriptions for selected AEDs were matched to patients with possible LGS by age, gender, US region, and dates of insurance coverage. Average healthcare utilization and costs per patient per year (PPPY) were evaluated for a 2-year postindex period and compared between the cohort with LGS and controls by insurance type. Costs were normalized to 2017 dollars at 3% per annum. Results: In the study, 6019 patients with possible LGS (53% male, mean age of 13 years, in both insurance groups) were identified: 2270 with commercial insurance and 3749 with Medicaid. The cohort with LGS used N8 times more services and N7 times more drugs than controls (all p b 0.001) in both insurance groups. The biggest contributors to service use PPPY were outpatient physician visits and home health services in the commercialinsured cohort with LGS and other outpatient visits and home health services in the Medicaid-insured cohort with LGS. Average total costs PPPY (services + drugs) were significantly higher for the cohort with LGS vs. controls: $65,026 (SD $34,324) vs. $2442 (SD $10,670) for commercial-insured and $63,930 (SD $45,761) vs. $3849 (SD $13849) for Medicaid-insured patients. The biggest cost contributors PPPY were inpatient care in the commercial-insured cohort with LGS and home health services in the Medicaid-insured cohort with LGS. Conclusions: Patients with possible LGS have significantly higher healthcare utilization and costs than patients without epilepsy or seizures. Our results suggest that direct costs associated with LGS are substantial and highlight the need for new and effective treatments.
Introduction
Lennox-Gastaut syndrome (LGS) is a severe and treatment-resistant epilepsy syndrome for which the burden of illness remains poorly understood. Lennox-Gastaut syndrome is characterized by a triad of features including multiple severe seizure types, moderate to severe cognitive impairment, and diffuse slow spike-wave complexes on electroencephalographic (EEG) recordings [1] [2] [3] . A diverse set of symptomatic causes account for approximately 70-80% of all cases of LGS, with 
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Epilepsy & Behavior j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / y e b e h genetic or unknown etiologies comprising the remainder [4] [5] [6] [7] . Because the signs typically present between ages 3 and 5 [3] , LGS is sometimes incorrectly perceived as a childhood-only epilepsy syndrome; however, symptoms and comorbidities continue throughout adulthood, making
LGS a lifelong condition. Despite the development of several new therapeutic options, the overall prognosis for LGS remains poor. The majority of individuals with LGS experience lifelong cognitive and behavioral problems, with intractable seizures persisting into adulthood in 80-90% of patients [3, 8, 9] . In addition to a high-seizure burden, the seizure types prevalent in LGS pose significant risks to patients. Drop seizures occur in at least half of patients, which may lead to accidents or serious injury [6, 10] , and nonconvulsive status epilepticus is also common [11] . Furthermore, all-cause mortality risk among children with LGS has been reported as 14 times greater than that of the general population, with most deaths resulting from neurological causes related to prolonged seizures or status epilepticus [12] .
Given the high-seizure burden, comorbidities, and poor prognosis, the clinical burden of illness in LGS is substantial; however, there is a paucity of data on the financial burden of healthcare utilization and costs associated with the management of patients with LGS. Health insurance claims databases are an important resource to examine realworld data on the economic burden of disease, but in the absence of an International Classification of Diseases (ICD-9) diagnosis code, identifying patients with LGS in claims data is challenging. In October 2015, the 10th revision of ICD Clinical Modification (ICD-10 CM) implemented a diagnosis code for LGS, but it will take several more years before this coding can be reliably used in retrospective data analyses.
Two recent retrospective health insurance claim studies found substantial healthcare utilization and costs associated with LGS using specific inclusion criteria (≥2 claims for epilepsy and ≥1 claim for developmental disorder or cognitive impairment) [13] and random forest predictive modeling [14] . By using inclusion criteria similar to Francois et al. before employing a predictive modeling process similar to Piña-Garza et al., we aimed to quantify the healthcare utilization and costs of patients identified with LGS in claims data (study group) compared with patients without evidence of epilepsy or seizure disorders (control group).
Methods

Study design
For this retrospective study, Truven Health Analytics MarketScan® Research Databases were queried for US health insurance claims data (commercial and Medicaid) among patients with medical and drug coverage between October 2010 and September 2015. These databases include claims for healthcare and outpatient pharmacy services for approximately 60 million employees, dependents, and retirees with commercial or Medicaid insurance coverage.
Patient selection
Because LGS lacks a distinctive ICD-9 diagnosis code, patients with LGS were identified using a multistep selection process. Data were obtained on patients with an ICD-9 diagnosis code for epilepsy or related conditions (345.*, 759.9, or 780.32). To select patients for further consideration, three initial inclusion criteria were required: (1) a diagnosis code for refractory epilepsy (ICD-9 345.01, 345.11, 345.81 or 345.91); (2) a diagnosis code for developmental delay/intellectual disability (Supplemental Appendix 1); and (3) a prescription for at least one selected antiepileptic drug (AED) ( Table 1) . Patients with diagnosis codes for conditions suggestive of etiologies other than LGS (Supplemental Appendix 1) were excluded.
To further identify patients with LGS, we adapted the statistical modeling approach developed by Piña-Garza et al. [14] and selected a priori additional variables for use with this data set, all of which were evaluated in all available data. Consistent with Piña-Garza et al., we selected rufinamide use as a disease indicator of LGS. Characteristics predictive of rufinamide use were established by multivariate linear regression among rufinamide users fulfilling all other inclusion criteria compared with patients with tuberous sclerosis complex (TSC), identified by ICD-9 diagnosis code 759.5.
While patients with TSC also suffer intractable seizures, it is a distinct medical condition characterized by nonmalignant but potentially lifethreatening tumor growth that impacts multiple organ systems [15] . Despite the possible overlap between patients with TSC and LGS, investigators judged that patients with TSC could function as an adequate comparator group in regression modeling because TSC presents a clinical pattern distinctively different from typical LGS, and the impact of possible overlap in populations with TSC and LGS was evaluated and found to be minimal. Characteristics that significantly predicted LGS in the multivariate linear regression are shown in Table 2 . Together with intercept values (− 6.1768 for commercial; − 4.9015 for Medicaid), the predictors in Table 2 were applied in a statistical model to evaluate the probability of LGS in each patient meeting inclusion criteria. The strength of the predictive model was assessed by applying it to the population in which it was created and establishing sensitivity and specificity, reported here for a 50% likelihood of LGS. Patients not using rufinamide whose aggregate probability of LGS failed to reach a threshold of 50% (selected on 87% sensitivity and 93-97% specificity) were excluded from the study as probably not having LGS. Remaining patients with ≥ 2 years of continuous insurance starting at the index date (the date of epilepsy/seizure diagnosis or prescription for any AED) were included in the study as patients with possible LGS. Patients lacking diagnoses of epilepsy or seizures (345.*, 780.3* or 759.5) and outpatient claims for any selected AEDs (Table 1) were initially chosen as controls at random on a 3:1 basis from persons matched to a particular patient with epilepsy by age, sex, one of four US geographic regions, and insurance type. A single patient having 2 years of continuous insurance most proximal to the index date of the patient with possible LGS was selected as a matched control.
In the initially evaluated patients with epilepsy, 1.6% had no matched control with 2 years of continuous insurance and were therefore excluded.
Healthcare utilization and cost analyses
All-cause utilization and costs were assessed during an outcome period of 2 years beginning with the index date (for the cohort with LGS) or the most proximal 2-year period of continuous insurance (for the control cohort). Table 1 shows how contemporaneous healthcare claims were organized into discrete episodes representing both IP and OP claims of service use.
Patient demographics, including age and geographic location, were evaluated as of the index date. Costs are presented from the health plan perspective. Allowed cost (cost after discounts, before application of deductibles, copays, coinsurance, and coordination of benefits) was normalized to 2017 dollars at 3% per annum and averaged per patient per year (PPPY). Because of a skewed distribution commonly found in healthcare cost data, cost outliers (5 highest-cost and 5 lowest-cost study patients, plus their controls) were withheld from the analysis of cost outcomes, as were matched pairs in which either individual was missing cost data, but had intact utilization data (commercial-insured [n = 3, 0.1%]; Medicaid-insured [n = 228; 6.1%]). Additionally, analyses of epilepsy-related services and characteristics during the outcome period were conducted as an assessment of patients with possible LGS.
Statistical analysis
Significance of difference in means between the cohort with LGS and controls and between patients with possible LGS with commercial and Medicaid insurance was assessed for utilization and cost in each category by paired t-test, adjusted for multiplicity by the Bonferroni correction of Holm, with a p-value b 0.05 denoting statistical significance. All statistical analyses were carried out using SAS/STAT software, version [9.4] of the SAS System for Windows, copyright ©2002-2008. 
Results
Patient demographics and characteristics
In the database, 6019 individuals were identified with possible LGS; 2270 covered under commercial insurance and 3749 covered under Medicaid insurance. An equal number of matched controls were identified within the database. The mean age in each insurance group was 13 years, ranging from 0 to 62 years. There was a higher proportion of males in both insurance groups (53%), consistent with epidemiological reports of patients with this condition [16] . The most frequently used AED at index was levetiracetam. A somewhat higher percentage of Medicaid-insured patients used levetiracetam compared with commercial-insured patients (45.1% vs. 38.6%), otherwise, AED use at index was similar between commercial and Medicaid cohorts ( Table 3) .
Evaluation of characteristics found solely in the cohort with LGS confirmed identification of a study population with substantial usage of epilepsy-related treatments and services (Table 4) . Vagus nerve stimulation was used in 14-15% of patients. Approximately one-third of patients with possible LGS (mean age, 13 years) had claims for wheelchair or walker use and claims related to enteral nutrition.
Total direct costs
Individuals with possible LGS had substantially higher costs for medical services and drugs than matched controls (Fig. 1) . Total PPPY costs for the cohort with LGS compared with controls were $65,930 (SD $34,324) vs. $2442 (SD $10,670) for commercial-insured patients and $63,930 (SD $45,761) vs. $3849 (SD $13849) for Medicaidinsured patients. Annual costs for services were 17 to 20 times higher for patients with possible LGS than matched controls. Similarly, annual costs for drugs were 16 to 38 times higher for patients with possible LGS compared with matched controls. Differences in total costs between commercial and Medicaid claims were insignificant; patients covered under Medicaid insurance averaged ≈$1400 more in healthcare services and ≈$2500 less in drugs.
Healthcare utilization by category
Patients with possible LGS used substantially more services and drugs than matched controls ( Fig. 2 and Supplemental Appendix 2a). Differences in utilization patterns between the cohorts with LGS and controls were particularly apparent in categories defined as other OP visits, home health, and other drugs for which the cohort with LGS accessed up to 29 times more services than matched controls.
For other OP visits (nonfacility, nonphysician services), the mix of services differed between patients with possible LGS and controls. Under commercial insurance, the most frequently used services (by CPT© or 
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All comparisons LGS vs control, p < 0.0001 HCPCS code) among patients with possible LGS were therapeutic activities (97530), therapeutic exercises (97110), and speech/hearing therapy (92570) while the most utilized services among control cohorts were therapeutic exercises (97110), psychotherapy visits (90806), and chiropractic manipulation (98941). Under Medicaid, the most frequently used services for patients with possible LGS were other specified case management (G9012), therapeutic activities (97530), and speech/ hearing therapy (92570) while the most often utilized services among patients in the control cohorts were dental services and psychosocial rehabilitation (H2017). Among the cohort with LGS, type of insurance coverage was associated with differences in utilization patterns. Commercial-insured patients used more services PPPY than Medicaid-insured patients in the physician visits, IP admissions, and equipment/supply categories (all p b 0.0001). Medicaid-insured patients used more home health, other OP visits, and ED visits without admission categories (all p b 0.0001) than commercial-insured patients.
Healthcare costs by category
Annual costs for specific categories of medical services and drugs generally followed previously noted utilization patterns but showed even greater differences between patients with possible LGS and matched controls (Fig. 3 and Supplemental Appendix 2b). Commercialinsured patients with possible LGS had annual IP admission costs nearly 50 times higher and annual hospital OP visit costs nearly 20 times higher than matched controls. Medicaid-insured patients with possible
LGS demonstrated similar cost patterns with IP admission costs nearly 15 times higher and hospital OP visits nearly 12 times higher than matched controls and home health costs nearly 40 times higher and other OP costs over 11 times higher than matched controls. Total annual drug costs were impacted by costs of individual drugs. Among commercial-insured patients with possible LGS, vigabatrin was the biggest cost contributor, adding $1433 PPPY to total annual drug costs of $13,979 despite being used by only 3% of patients. Rufinamide and lamotrigine added a total of $2330 PPPY but were used by a much higher percentage of commercial-insured patients, 19% and 40%, respectively. Among Medicaid-insured patients with possible LGS, rufinamide and levetiracetam were the biggest cost contributors adding $1782 PPPY to total annual drug costs of $11,493.
Among patients with possible LGS, differences noted in utilization patterns between insurance types were generally reflected in cost patterns. Commercial-insured patients had higher annual service costs than Medicaid-insured patients for IP admissions, hospital OP visits, and physician visits and lower costs for home health visits and other OP visits.
Discussion
Our study demonstrates that patients identified with possible LGS comprise a high-cost medical population who utilize healthcare resources significantly more than patients without epilepsy or seizures. Patients with possible LGS averaged nearly 2 hospital visits (IP admission and ED visits) a year; had filled prescriptions for 2 AEDs and more than 2 other drugs each month; and had annual costs over $60,000 higher than controls.
Only a few studies have examined utilization and costs associated with LGS, comparing patients with LGS to those with nonrefractory epilepsy [14] or comparing patients who did or did not initiate clobazam use [13] . In both cases, their results were comparable to the observed direct costs in our study. We attempted to build upon methods outlined by Piña-Garza et al. [14] and Francois et al. [13] , and to the best of our knowledge, this is the first study to compare direct costs of patients with possible LGS to a matched population without epilepsy or seizure conditions by insurance type. The observed direct costs of patients with LGS are substantially higher than patients with other disabilities. According to a Kaiser Family Foundation analysis of 2014 Medicaid data (normalized to 2017 dollars for comparison), average annual Medicaid spending per enrollee with disabilities is $20,500 for children and nearly the same for nonelderly adults [17] . The average $64,000 PPPY cost of services and drugs for patients with possible LGS covered under Medicaid in our study is over three times this average. Indeed, the PPPY costs of patients with LGS are more comparable to costs of adult patients with chronic diseases that typically do not start until later in life, such as advanced chronic kidney disease ($45,000 in Stage 3b, $79,000 in Stages 4-5; in 2017 dollars) [18] . Given that LGS is typically diagnosed between ages 3 and 8 and is a lifelong syndrome, this average utilization accumulating over several decades amounts to staggering costs.
The patterns of healthcare costs and utilization captured in this study reflect important differences in service use for patients enrolled in commercial vs. Medicaid plans. Habilitation services such as home health and case management frequently appear in Medicaid claims of patients identified with LGS but not in commercial insurance claims because most commercial health plans in the US offer minimal or no coverage for these services. Given how seizure severity and frequency are related to disability, morbidity, and long-term outcome for patients with LGS, it stands to reason that effective treatment of seizures may reduce overall disability and healthcare utilization. We need to further understand how preventing or reducing seizures may uniquely impact the utilization and costs of patients covered by Medicaid vs. commercial insurance plans. Clearer expectations regarding changes in care patterns that are driven by introducing new, effective treatments could help to identify improvements in insurance benefit design.
Limitations
Our identification methods were built upon previously published methodologies while adding additional inclusion requirements to identify patients with LGS in claims data as accurately as possible. Because of limitations in available data, neither our methodology nor those of our predecessors have been validated. Future studies validating identification methods for LGS and similar conditions in claims data will be important. Our study reports direct costs associated with LGS but does not contain information on indirect cost burdens. Studies on measures of quality-adjusted life years and health-related quality of life are needed to better describe the indirect costs and to fully understand the overall cost burden of LGS. Patients with LGS who live at home require a considerable time commitment on behalf of the caregiver because of frequent severe seizures, as well as cognitive and behavioral comorbidities [19] . The full-time burden on caregivers may influence career choices, lead to under-/unemployment, impact sleep, increase stress, affect social relationships, and negatively influence mental health. Such indirect costs on caregivers of patients with LGS have been poorly quantified but are likely substantial.
Conclusions
Despite the availability of six FDA-approved AEDs for LGS and evidence that some therapies may improve seizure control, our results suggest that annual all-cause utilization and costs remain markedly high in patients with possible LGS, emphasizing the need for new and more effective treatments. Two recent clinical trials demonstrated safety and efficacy of a pharmaceutical formulation of highly purified cannabidiol to treat refractory seizures in patients with LGS [20, 21] .
Exploring effects of cannabidiol and other new treatments will be needed to fully understand their impact on burden of illness and healthcare utilization in LGS. Better understanding of utilization and cost patterns associated with LGS may help to allocate resources more efficiently while improving overall care for these patients. As payment models shift to value-based care models, such work will become even more important.
